IGNE logo

Igene Biotechnology, Inc. (IGNE) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Igene Biotechnology, Inc. (IGNE), Basic Materials sektöründe faaliyet gösteriyor, son olarak $'dan işlem görüyor ve 0 piyasa değerine sahip. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 47/100 (ihtiyatlı) olarak derecelendirilmiştir.

Son analiz: 16 Mar 2026
47/100 AI Puanı

Igene Biotechnology, Inc. (IGNE) Malzemeler ve Emtia Maruziyeti

CEOJoseph L. Downs
Çalışanlar18
MerkezColumbia, US
Halka Arz Yılı1995

Igene Biotechnology, Inc. is a leader in the production of natural astaxanthin, catering to the nutritional needs of both human and animal markets, while offering research and development services in microbial strain improvement.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 16 Mar 2026

Yatırım Tezi

Igene Biotechnology, Inc. operates within a niche market that is experiencing increasing demand for natural ingredients in both human and animal nutrition sectors. The company's focus on natural astaxanthin provides a unique value proposition, as this ingredient is essential for enhancing the color and nutritional value of farmed fish, a growing segment within the aquaculture industry. With a gross margin of 25.7%, Igene demonstrates its ability to maintain profitability despite challenges, while its negative profit margin of -3.6% indicates potential areas for operational improvement. The global astaxanthin market is projected to grow significantly, driven by rising consumer awareness of health benefits associated with natural pigments. Furthermore, Igene's capabilities in microbial strain improvement and fermentation process development position it to capitalize on emerging trends in the nutraceutical space. However, investors should remain cautious of the company's current P/E ratio of -0.11, which reflects its ongoing financial challenges and the need for strategic initiatives to return to profitability.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Market Cap: $0.00B, indicating a currently unvalued position in the market.
  • P/E Ratio: -0.11, highlighting ongoing financial challenges.
  • Profit Margin: -3.6%, indicating potential areas for operational improvement.
  • Gross Margin: 25.7%, showcasing the company's ability to maintain profitability in its niche.
  • Beta: -23.34, suggesting extreme volatility in stock performance.

Rakipler & Benzerleri

Güçlü Yönler

  • Specialized expertise in natural astaxanthin production.
  • Established relationships within the nutraceutical and feed industries.
  • Strong R&D capabilities for product innovation.

Zayıflıklar

  • Small workforce of 18 employees, limiting operational capacity.
  • Negative profit margin indicating financial challenges.
  • Dependence on a niche market for revenue.

Katalizörler

  • Upcoming: Expansion of product offerings in the nutraceutical sector.
  • Ongoing: Development of new microbial strains for improved fermentation processes.
  • Ongoing: Increased demand for natural astaxanthin in aquaculture markets.

Riskler

  • Potential: Regulatory changes impacting the agricultural inputs sector.
  • Ongoing: Competition from other companies producing natural pigments.
  • Ongoing: Financial instability due to negative profit margins.

Büyüme Fırsatları

  • Growth opportunity 1: The global astaxanthin market is projected to reach $1.5 billion by 2027, growing at a CAGR of 15%. Igene's established expertise in natural astaxanthin production positions it to capture a significant share of this expanding market. By enhancing its production capabilities and marketing efforts, Igene can leverage this growth trend to increase revenue and market presence.
  • Growth opportunity 2: The nutraceutical sector is increasingly leaning towards natural ingredients, with a projected market size of $300 billion by 2025. Igene's ability to supply high-quality natural ingredients aligns with this trend, providing substantial growth potential. By expanding its product offerings and targeting health-conscious consumers, Igene can tap into this lucrative market.
  • Growth opportunity 3: The increasing awareness of the benefits of natural pigments in aquaculture presents an opportunity for Igene to expand its client base among fish farmers. With the global aquaculture market expected to grow at a CAGR of 5.3% through 2027, Igene can enhance its sales by promoting the advantages of its astaxanthin products to fish farming operations.
  • Growth opportunity 4: Igene's research and development capabilities in microbial strain improvement can lead to innovative product offerings, enhancing its competitive advantage. The global market for microbial products in agriculture is anticipated to grow significantly, allowing Igene to diversify its revenue streams through new product development.
  • Growth opportunity 5: The demand for analytical chemistry services is on the rise, particularly in food safety and quality assurance. By expanding its analytical services to include more comprehensive testing for carotenoids and other nutrients, Igene can increase its service offerings and attract a broader clientele within the food and feed industries.

Fırsatlar

  • Growing global demand for natural ingredients in nutrition.
  • Expansion potential in the aquaculture market.
  • Increasing interest in microbial products for agriculture.

Tehditler

  • Intense competition within the agricultural inputs sector.
  • Market volatility affecting ingredient prices.
  • Regulatory challenges in food and feed industries.

Rekabet Avantajları

  • Established expertise in natural astaxanthin production.
  • Strong R&D capabilities in microbial strain improvement.
  • Unique analytical services for carotenoid verification.

IGNE Hakkında

Founded in 1981, Igene Biotechnology, Inc. has established itself as a pioneering force in the agricultural inputs sector, specializing in the research, development, production, and commercialization of specialty ingredients aimed at enhancing human and animal nutrition. Originally known as IGI Biotechnology, Inc., the company rebranded to its current name in April 1986. Headquartered in Columbia, Maryland, Igene focuses on natural astaxanthin, a critical nutrient that serves as a pigment source for coloring farmed salmon and trout species. Beyond astaxanthin, the company also supplies a range of ingredients and finished products to the nutraceutical and feed industries. Igene's expertise extends to providing research and development services for microbial strain improvement and fermentation process development, scaling operations from shake flasks to pilot plants and commercial-sized fermentors. Additionally, the company offers analytical chemistry services for the identification and quantization of carotenoids in various food and feed products, including the verification of wild versus farm-raised salmonids. With a dedicated workforce of 18 employees, Igene Biotechnology is positioned to leverage its innovative capabilities to meet the growing demand for natural nutritional solutions in an increasingly health-conscious market.

Ne Yaparlar

  • Research and develop specialty ingredients for human and animal nutrition.
  • Produce natural astaxanthin for coloring farmed salmon and trout.
  • Supply nutraceutical and feed industry products.
  • Provide research and development services for microbial strain improvement.
  • Offer fermentation process development and scale-up services.
  • Deliver analytical chemistry services for carotenoid identification and quantization.

İş Modeli

  • Generate revenue through the sale of specialty ingredients and products.
  • Offer research and development services to clients in the nutraceutical and feed industries.
  • Provide analytical services to verify the quality and source of carotenoids.

Sektör Bağlamı

The agricultural inputs industry is witnessing a shift towards natural and sustainable ingredients, driven by consumer demand for healthier food options and environmentally friendly practices. As aquaculture continues to expand globally, the need for natural colorants like astaxanthin is increasing, positioning Igene Biotechnology favorably within this growth trajectory. The global astaxanthin market is expected to reach approximately $1.5 billion by 2027, with a CAGR of around 15%. Igene's focus on research and development further enhances its competitive edge, allowing it to innovate and meet evolving market demands.

Kilit Müşteriler

  • Aquaculture businesses requiring natural colorants for fish.
  • Nutraceutical companies seeking high-quality ingredients.
  • Feed manufacturers looking for specialized additives.
AI Güveni: 65% Güncellendi: 16 Mar 2026

Finansallar

Grafik & Bilgi

Igene Biotechnology, Inc. (IGNE) hisse senedi fiyatı: Price data unavailable

Son Haberler

IGNE için son haber bulunmamaktadır.

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

IGNE için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

IGNE için Wall Street fiyat hedefi analizi.

MoonshotScore

47/100

Bu puan ne anlama geliyor?

MoonshotScore, IGNE'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

Yönetim: Joseph L. Downs

CEO

Joseph L. Downs has been at the helm of Igene Biotechnology, Inc. for several years, bringing extensive experience in biotechnology and business management. He has a strong background in developing innovative solutions for the agricultural sector, with a focus on enhancing product quality and operational efficiency. His leadership is characterized by a commitment to advancing the company's research and development initiatives.

Sicil: Under Joseph L. Downs' leadership, Igene has made significant strides in refining its production processes and expanding its product offerings. His strategic decisions have positioned the company to better meet the needs of its clients in the nutraceutical and feed industries.

IGNE OTC Piyasa Bilgileri

The OTC Other tier refers to stocks that do not meet the criteria for higher tiers like OTCQX or OTCQB, often indicating lower visibility and liquidity. Companies in this tier may have less stringent reporting requirements, which can affect investor confidence.

  • OTC Katmanı: OTC Other
  • Açıklama Durumu: Unknown
Likidite: Liquidity can be a concern for stocks trading on the OTC market, as they may experience lower trading volumes and wider bid-ask spreads. This can make it more challenging for investors to execute trades without impacting the stock price significantly.
OTC Risk Faktörleri:
  • Less regulatory oversight compared to stocks listed on major exchanges.
  • Potential for lower liquidity, making it difficult to buy or sell shares.
  • Higher volatility due to lower trading volumes and investor interest.
Durum Tespiti Kontrol Listesi:
  • Review recent financial statements and disclosures.
  • Assess the company's market position and competitive landscape.
  • Evaluate management's track record and strategic vision.
  • Investigate any legal or regulatory issues affecting the company.
  • Consider the overall market conditions and trends in the agricultural inputs sector.
Meşruiyet Sinyalleri:
  • Established company history since 1981.
  • Focus on R&D and innovation in specialty ingredients.
  • Partnerships with clients in the nutraceutical and feed industries.

Yatırımcılar Igene Biotechnology, Inc. (IGNE) Hakkında Ne Soruyor

IGNE için değerlendirilmesi gereken temel faktörler nelerdir?

Igene Biotechnology, Inc. (IGNE) şu anda yapay zeka skoru 47/100, düşük puanı gösteriyor. Temel güçlü yan: Specialized expertise in natural astaxanthin production.. İzlenmesi gereken birincil risk: Potential: Regulatory changes impacting the agricultural inputs sector.. Bu bir finansal tavsiye değildir.

IGNE MoonshotScore'u nedir?

IGNE şu anda MoonshotScore'da 47/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

IGNE verileri ne sıklıkla güncellenir?

IGNE fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler IGNE hakkında ne diyor?

IGNE için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

IGNE'a yatırım yapmanın riskleri nelerdir?

IGNE için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Regulatory changes impacting the agricultural inputs sector.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

IGNE'ın P/E oranı nedir?

IGNE için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için IGNE'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

IGNE aşırı değerli mi, yoksa düşük değerli mi?

Igene Biotechnology, Inc. (IGNE)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

IGNE'ın temettü verimi nedir?

Igene Biotechnology, Inc. (IGNE) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Data may be subject to change as new information becomes available.
Veri Kaynakları

Popüler Hisseler